Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with Docetaxel and Cisplatin in Advanced Ovarian Cancer
NCT03373058Phase 3Unknown
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, Cisplatin micelle injection (HA132) in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Cancer Center of Guangzhou Medical University. Status: unknown.
02
Drugs
docetaxelCisplatin micelle injection (HA132)
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03373058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373058.